June, 14 2026 Sunday 13:54 Hrs
Last update 11-9-2025
  • SENSEX :   75,527.95

  • Commodity broking firm in India1,695.40( 2.30%) 12-Jun-2026
Positive
Sensex 75527.95 1695.40  (2.30) 12-Jun-2026
Previous Day Close 73832.55
Today's High/Low
High Low
  •  
  •  
75608.02 74453.39

Hot Pursuit - Detailed News

Dr. Reddy's Labs oncology drug Bosutinib Tablets in United States
13-Jun-26   16:55 Hrs IST

The pharmaceutical major has collaborated with MSN Laboratories (MSN), a leading pharmaceutical company in India, on this product.

Dr. Reddy's holds the exclusive marketing rights for the product in the United States. MSN is responsible for the development and manufacturing of the product.

Bosutinib Tablets was a first-to-file product and is eligible for 180-days of generic drug exclusivity for this strength, in the U.S.

The Bosulif brand had U.S. sales of approximately $253.8 million for the latest 12-month period ended April 2026, according to IQVIA National Sales Perspectives data.

Milan Kalawadia, CEO- North America, Dr. Reddy's Laboratories, Inc. said: This launch highlights our commitment to leading with timely market entry for high-priority therapies while broadening access for both patients and healthcare providers.

With this launch, we remain focused on strengthening our oncology portfolio and partnering across the healthcare system to ensure that critical treatments are both accessible and affordable.

Hyderabad-based Dr. Reddy's Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC.

The company had reported a 86.14% decline in consolidated net profit to Rs 220.9 crore on 11.51% drop in revenue from operations to Rs 7,546.4 crore in Q4 FY26 over Q4 FY25.

The scrip shed 0.09% to end at Rs 1273.90 on the BSE on Friday.

Powered by Capital Market - Live News

Top

Attention Investor:

Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers/Depository Participant.     KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, ,Mutual ).    No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.